Free Trial

Zevra Therapeutics (ZVRA) Financials

Zevra Therapeutics logo
$7.21 -0.04 (-0.52%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Zevra Therapeutics

Annual Income Statements for Zevra Therapeutics

This table shows Zevra Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-27 -46 -106
Consolidated Net Income / (Loss)
-27 -46 -106
Net Income / (Loss) Continuing Operations
-27 -46 -106
Total Pre-Tax Income
-27 -46 -90
Total Operating Income
-43 -50 -87
Total Gross Profit
9.94 25 16
Total Revenue
10 27 24
Operating Revenue
10 27 24
Total Cost of Revenue
0.22 2.17 7.42
Operating Cost of Revenue
0.22 2.17 7.42
Total Operating Expenses
53 75 103
Selling, General & Admin Expense
15 34 55
Research & Development Expense
37 40 42
Amortization Expense
- 0.77 6.24
Total Other Income / (Expense), net
16 3.56 -3.14
Interest Expense
-1.18 -3.04 5.18
Other Income / (Expense), net
15 0.52 2.04
Income Tax Expense
-0.03 0.00 15
Basic Earnings per Share
($0.78) ($1.30) ($2.28)
Weighted Average Basic Shares Outstanding
34.49M 35.45M 46.25M
Weighted Average Diluted Shares Outstanding
34.54M 43.43M 54.12M
Weighted Average Basic & Diluted Shares Outstanding
34.54M 43.43M 54.12M

Quarterly Income Statements for Zevra Therapeutics

This table shows Zevra Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-6.62 5.75 -13 -2.57 -10 -20 -17 -20 -33 -36
Consolidated Net Income / (Loss)
-6.62 5.75 -13 -2.57 -10 -20 -17 -20 -33 -36
Net Income / (Loss) Continuing Operations
-6.62 5.75 -13 -2.57 -10 -20 -17 -20 -33 -36
Total Pre-Tax Income
-6.65 6.47 -13 -2.65 -10 -20 -17 -20 -33 -20
Total Operating Income
-6.63 -9.31 -13 -6.25 -15 -15 -20 -24 -27 -15
Total Gross Profit
2.73 2.00 3.05 7.79 2.75 12 3.25 0.88 1.39 11
Total Revenue
2.87 2.02 3.18 8.47 2.90 13 3.43 4.45 3.70 12
Operating Revenue
2.87 2.02 3.18 8.47 2.90 13 3.43 4.45 3.70 12
Total Cost of Revenue
0.14 0.02 0.13 0.68 0.14 1.23 0.18 3.57 2.30 1.37
Operating Cost of Revenue
0.14 0.02 0.13 0.68 0.14 1.23 0.18 3.57 2.30 1.37
Total Operating Expenses
9.36 11 16 14 18 27 24 25 29 26
Selling, General & Admin Expense
3.97 4.77 7.23 6.61 5.82 15 9.93 13 16 16
Research & Development Expense
5.39 6.54 8.66 7.43 12 11 12 11 11 8.35
Amortization Expense
- - 0.00 0.00 0.00 0.77 1.53 1.55 1.55 1.62
Total Other Income / (Expense), net
-0.02 16 -0.49 3.61 5.17 -4.74 3.79 3.94 -5.92 -4.95
Interest Expense
-0.09 -0.65 -0.86 -1.36 -1.37 0.55 -0.19 1.84 1.26 2.27
Other Income / (Expense), net
-0.12 15 -1.35 2.25 3.80 -4.19 3.60 5.78 -4.66 -2.69
Income Tax Expense
-0.03 0.72 -0.10 -0.07 0.18 - -0.07 0.07 0.00 15
Basic Earnings per Share
($0.19) $0.16 ($0.38) ($0.08) ($0.30) ($0.54) ($0.40) ($0.48) ($0.69) ($0.71)
Weighted Average Basic Shares Outstanding
34.49M 34.49M 34.47M 33.90M 34.72M 35.45M 41.78M 41.90M 47.81M 46.25M
Weighted Average Diluted Shares Outstanding
34.50M 34.54M 33.88M 33.93M 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M
Weighted Average Basic & Diluted Shares Outstanding
34.50M 34.54M 33.88M 33.93M 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M

Annual Cash Flow Statements for Zevra Therapeutics

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-47 -22 -9.26
Net Cash From Operating Activities
-19 -34 -70
Net Cash From Continuing Operating Activities
-19 -34 -70
Net Income / (Loss) Continuing Operations
-27 -46 -106
Consolidated Net Income / (Loss)
-27 -46 -106
Depreciation Expense
0.94 1.01 6.39
Amortization Expense
- 0.00 -0.89
Non-Cash Adjustments To Reconcile Net Income
7.79 8.74 38
Changes in Operating Assets and Liabilities, net
-0.68 2.77 -7.19
Net Cash From Investing Activities
-37 -17 -22
Net Cash From Continuing Investing Activities
-37 -17 -22
Purchase of Property, Plant & Equipment
-0.09 -0.30 0.00
Acquisitions
-14 -30 -6.00
Purchase of Investments
-24 -46 -41
Sale and/or Maturity of Investments
1.33 59 25
Net Cash From Financing Activities
8.35 28 82
Net Cash From Continuing Financing Activities
8.35 28 82
Repayment of Debt
-0.02 -18 -45
Repurchase of Common Equity
-4.72 -3.45 0.00
Issuance of Debt
13 42 59
Issuance of Common Equity
0.32 6.32 66
Other Financing Activities, net
-0.03 0.69 2.34
Effect of Exchange Rate Changes
0.20 - 0.45
Cash Interest Paid
0.32 0.46 5.26

Quarterly Cash Flow Statements for Zevra Therapeutics

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-6.72 -4.59 -25 26 -23 -0.22 -0.20 -3.59 15 -20
Net Cash From Operating Activities
-6.60 -4.46 -4.05 -8.70 -4.63 -16 -16 -19 -18 -16
Net Cash From Continuing Operating Activities
-6.60 -4.46 -4.05 -8.70 -4.63 -16 -16 -19 -18 -16
Net Income / (Loss) Continuing Operations
-6.62 5.75 -13 -2.57 -10 -20 -17 -20 -33 -36
Consolidated Net Income / (Loss)
-6.62 5.75 -13 -2.57 -10 -20 -17 -20 -33 -36
Depreciation Expense
0.40 0.30 0.08 0.08 0.06 0.79 1.56 1.56 1.62 1.65
Non-Cash Adjustments To Reconcile Net Income
1.90 -15 3.60 1.66 -1.31 4.79 0.06 2.37 11 24
Changes in Operating Assets and Liabilities, net
-2.28 3.99 5.50 -7.87 6.99 -1.85 -1.16 -3.12 2.46 -5.37
Net Cash From Investing Activities
0.27 -0.06 -18 34 -44 11 15 -0.13 -31 -5.47
Net Cash From Continuing Investing Activities
0.27 -0.06 -18 34 -44 11 15 -0.13 -31 -5.47
Purchase of Investments
- -0.03 - - -54 25 - - -41 0.33
Sale and/or Maturity of Investments
0.30 - -18 52 9.50 16 15 - 10 0.20
Net Cash From Financing Activities
-0.41 -0.26 -3.75 0.95 26 5.00 1.22 15 65 0.80
Net Cash From Continuing Financing Activities
-0.41 -0.26 -3.75 0.95 26 5.00 1.22 15 65 0.80
Issuance of Common Equity
- - 0.00 0.17 0.05 6.11 1.22 0.48 65 -0.89
Other Financing Activities, net
-0.42 -0.63 -0.42 1.11 -0.00 - 0.00 0.65 - 1.68
Cash Interest Paid
0.12 0.16 0.07 0.19 0.20 - 0.14 2.00 1.53 1.59

Annual Balance Sheets for Zevra Therapeutics

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
115 172 178
Total Current Assets
93 87 86
Cash & Equivalents
65 43 34
Short-Term Investments
17 25 36
Accounts Receivable
8.30 17 11
Inventories, net
- 0.00 1.97
Prepaid Expenses
1.69 1.82 4.05
Plant, Property, & Equipment, net
0.79 0.74 0.36
Total Noncurrent Assets
22 85 92
Long-Term Investments
20 0.00 6.01
Goodwill
0.00 4.70 4.70
Intangible Assets
0.00 69 69
Other Noncurrent Operating Assets
1.71 11 12
Total Liabilities & Shareholders' Equity
115 172 178
Total Liabilities
40 110 138
Total Current Liabilities
12 74 34
Short-Term Debt
0.00 38 0.00
Accounts Payable
6.17 28 25
Other Current Liabilities
5.85 7.62 8.61
Total Noncurrent Liabilities
28 37 104
Long-Term Debt
13 5.07 60
Noncurrent Deferred Revenue
- 0.00 14
Other Noncurrent Operating Liabilities
15 32 30
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
75 62 40
Total Preferred & Common Equity
75 62 40
Preferred Stock
0.00 0.00 0.00
Total Common Equity
75 62 40
Common Stock
436 473 555
Retained Earnings
-354 -400 -505
Treasury Stock
-7.54 -11 -11
Accumulated Other Comprehensive Income / (Loss)
0.11 -0.04 0.63

Quarterly Balance Sheets for Zevra Therapeutics

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
120 107 106 139 151 144 192
Total Current Assets
85 104 103 137 63 61 99
Cash & Equivalents
70 40 66 43 43 39 54
Short-Term Investments
5.83 55 21 40 9.87 10.00 35
Accounts Receivable
6.58 7.82 14 9.93 8.31 8.95 7.79
Prepaid Expenses
2.66 1.17 2.02 1.66 1.87 2.69 2.28
Plant, Property, & Equipment, net
0.85 0.74 0.69 0.64 0.70 0.68 0.61
Total Noncurrent Assets
34 1.57 1.40 1.33 88 83 92
Long-Term Investments
31 0.00 0.00 0.00 - - 6.11
Goodwill
- - - - 4.70 4.70 4.70
Intangible Assets
- - - - 68 66 71
Other Noncurrent Operating Assets
2.10 1.57 1.40 1.33 15 12 10
Total Liabilities & Shareholders' Equity
120 107 106 139 151 144 192
Total Liabilities
26 35 37 72 102 112 122
Total Current Liabilities
8.43 16 18 22 30 30 34
Short-Term Debt
- - - - 0.00 0.00 0.00
Accounts Payable
4.28 10 11 13 23 20 24
Other Current Liabilities
4.15 5.52 7.74 8.63 7.12 10.00 10
Total Noncurrent Liabilities
17 20 19 50 73 81 87
Long-Term Debt
13 13 13 44 43 58 59
Other Noncurrent Operating Liabilities
4.53 6.66 6.06 5.92 30 23 28
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
94 71 68 67 49 32 70
Total Preferred & Common Equity
94 71 68 67 49 32 70
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
94 71 68 67 49 32 70
Common Stock
401 403 405 418 476 479 550
Retained Earnings
-300 -320 -325 -339 -416 -436 -470
Treasury Stock
-7.54 -11 -11 -11 -11 -11 -11
Accumulated Other Comprehensive Income / (Loss)
0.20 -0.06 -0.23 -0.22 0.14 0.42 -0.12

Annual Metrics and Ratios for Zevra Therapeutics

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
-64.53% 170.26% -14.02%
EBITDA Growth
-433.40% -77.83% -65.27%
EBIT Growth
-463.27% -75.42% -73.08%
NOPAT Growth
-650.72% -16.54% -75.40%
Net Income Growth
-212.94% -72.00% -129.13%
EPS Growth
0.00% 0.00% 0.00%
Operating Cash Flow Growth
-279.30% -79.17% -107.74%
Free Cash Flow Firm Growth
-512.15% -457.68% 44.91%
Invested Capital Growth
-2,196.46% 347.16% -35.86%
Revenue Q/Q Growth
-5.22% 65.80% -3.58%
EBITDA Q/Q Growth
24.62% -105.40% 1.50%
EBIT Q/Q Growth
23.49% -105.15% 1.44%
NOPAT Q/Q Growth
-17.93% -13.35% -0.30%
Net Income Q/Q Growth
24.00% -125.65% -17.67%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-23.93% -53.56% -0.13%
Free Cash Flow Firm Q/Q Growth
36.06% -45.92% 27.76%
Invested Capital Q/Q Growth
-1,864.08% 32.15% -28.71%
Profitability Metrics
- - -
Gross Margin
97.82% 92.09% 68.59%
EBITDA Margin
-266.11% -175.10% -336.55%
Operating Margin
-418.91% -180.63% -368.47%
EBIT Margin
-275.40% -178.76% -359.83%
Profit (Net Income) Margin
-263.48% -167.69% -446.85%
Tax Burden Percent
99.88% 100.00% 117.05%
Interest Burden Percent
95.79% 93.81% 106.09%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -316.15% -201.14%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -296.46% 16.61%
Return on Net Nonoperating Assets (RNNOA)
0.00% 248.92% -6.70%
Return on Equity (ROE)
-26.48% -67.23% -207.84%
Cash Return on Invested Capital (CROIC)
0.00% -234.58% -157.45%
Operating Return on Assets (OROA)
-22.54% -34.13% -48.49%
Return on Assets (ROA)
-21.57% -32.02% -60.21%
Return on Common Equity (ROCE)
-26.48% -67.23% -207.84%
Return on Equity Simple (ROE_SIMPLE)
-35.64% -74.44% -266.00%
Net Operating Profit after Tax (NOPAT)
-30 -35 -61
NOPAT Margin
-293.23% -126.44% -257.93%
Net Nonoperating Expense Percent (NNEP)
2.78% -19.69% -217.75%
Return On Investment Capital (ROIC_SIMPLE)
- -33.19% -61.41%
Cost of Revenue to Revenue
2.18% 7.91% 31.41%
SG&A Expenses to Revenue
148.00% 124.96% 232.37%
R&D to Revenue
368.72% 144.95% 178.28%
Operating Expenses to Revenue
516.72% 272.72% 437.06%
Earnings before Interest and Taxes (EBIT)
-28 -49 -85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-27 -48 -79
Valuation Ratios
- - -
Price to Book Value (P/BV)
2.11 3.83 11.22
Price to Tangible Book Value (P/TBV)
2.11 0.00 0.00
Price to Revenue (P/Rev)
15.59 8.64 18.85
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 5.75 18.14
Enterprise Value to Revenue (EV/Rev)
6.72 7.73 18.18
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.17 0.69 1.50
Long-Term Debt to Equity
0.17 0.08 1.50
Financial Leverage
-1.08 -0.84 -0.40
Leverage Ratio
1.23 2.10 3.45
Compound Leverage Factor
1.18 1.97 3.66
Debt to Total Capital
14.56% 40.87% 60.00%
Short-Term Debt to Total Capital
0.00% 36.03% 0.00%
Long-Term Debt to Total Capital
14.56% 4.84% 60.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
85.44% 59.13% 40.00%
Debt to EBITDA
-0.47 -0.89 -0.75
Net Debt to EBITDA
3.33 0.52 0.20
Long-Term Debt to EBITDA
-0.47 -0.11 -0.75
Debt to NOPAT
-0.43 -1.23 -0.98
Net Debt to NOPAT
3.02 0.72 0.26
Long-Term Debt to NOPAT
-0.43 -0.15 -0.98
Altman Z-Score
-1.80 -2.65 -3.13
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
7.72 1.18 2.53
Quick Ratio
7.58 1.15 2.35
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-16 -87 -48
Operating Cash Flow to CapEx
-20,125.81% -11,329.39% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -9.21
Operating Cash Flow to Interest Expense
0.00 0.00 -13.46
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -13.46
Efficiency Ratios
- - -
Asset Turnover
0.08 0.19 0.13
Accounts Receivable Turnover
2.07 2.14 1.69
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
12.11 35.90 43.25
Accounts Payable Turnover
0.05 0.13 0.28
Days Sales Outstanding (DSO)
176.50 170.64 215.53
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
7,568.82 2,903.54 1,325.23
Cash Conversion Cycle (CCC)
-7,392.32 -2,732.90 -1,109.70
Capital & Investment Metrics
- - -
Invested Capital
-15 37 24
Invested Capital Turnover
-1.30 2.50 0.78
Increase / (Decrease) in Invested Capital
-14 52 -13
Enterprise Value (EV)
68 212 429
Market Capitalization
158 237 445
Book Value per Share
$2.18 $1.71 $0.74
Tangible Book Value per Share
$2.18 ($0.33) ($0.64)
Total Capital
88 105 99
Total Debt
13 43 60
Total Long-Term Debt
13 5.07 60
Net Debt
-90 -25 -16
Capital Expenditures (CapEx)
0.09 0.30 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.04 -17 -18
Debt-free Net Working Capital (DFNWC)
81 51 52
Net Working Capital (NWC)
81 13 52
Net Nonoperating Expense (NNE)
-3.02 11 45
Net Nonoperating Obligations (NNO)
-90 -25 -16
Total Depreciation and Amortization (D&A)
0.94 1.01 5.50
Debt-free, Cash-free Net Working Capital to Revenue
-20.04% -61.25% -74.26%
Debt-free Net Working Capital to Revenue
795.31% 185.42% 220.07%
Net Working Capital to Revenue
795.31% 48.13% 220.07%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.20) ($1.30) ($2.28)
Adjusted Weighted Average Basic Shares Outstanding
34.49M 35.45M 46.25M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
34.54M 43.43M 54.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
34.54M 43.43M 54.12M
Normalized Net Operating Profit after Tax (NOPAT)
-30 -35 -61
Normalized NOPAT Margin
-293.23% -126.44% -257.93%
Pre Tax Income Margin
-263.80% -167.69% -381.76%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 -16.42
NOPAT to Interest Expense
0.00 0.00 -11.77
EBIT Less CapEx to Interest Expense
0.00 0.00 -16.42
NOPAT Less CapEx to Interest Expense
0.00 0.00 -11.77
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-17.64% -7.49% 0.00%

Quarterly Metrics and Ratios for Zevra Therapeutics

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
46.26% -21.69% -19.90% 551.54% 0.73% 538.97% 7.84% -47.47% 27.63% -6.79%
EBITDA Growth
-247.67% 325.55% -640.21% 84.24% -81.25% -403.37% -8.67% -319.18% -163.87% 11.34%
EBIT Growth
-256.77% 309.55% -619.80% 84.04% -71.47% -432.54% -19.08% -350.04% -176.44% 6.43%
NOPAT Growth
-198.20% -316.10% -590.21% 74.76% -131.87% -28.17% -59.66% -280.60% -77.73% -1.71%
Net Income Growth
-276.12% 312.73% -609.07% 89.30% -56.70% -445.95% -25.76% -674.39% -220.49% -79.67%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-141.69% -426.18% -13.85% -112.09% 29.86% -262.12% -299.63% -119.54% -291.98% -0.57%
Free Cash Flow Firm Growth
-27.05% 265.06% -18.89% 95.79% -982.07% -1,140.65% -1,584.23% -9,182.88% 38.15% 103.90%
Invested Capital Growth
-424.79% -2,196.46% -565.65% -148.51% 3,773.42% 347.16% 456.55% 774.15% 18.89% -35.86%
Revenue Q/Q Growth
121.08% -29.65% 57.07% 166.69% -65.82% 346.29% -73.49% 29.90% -16.95% 225.93%
EBITDA Q/Q Growth
74.52% 196.41% -330.52% 72.17% -192.99% -61.37% -2.99% -7.37% -84.43% 45.78%
EBIT Q/Q Growth
73.12% 186.27% -343.77% 71.77% -188.83% -67.31% -7.79% -6.69% -77.42% 43.37%
NOPAT Q/Q Growth
73.25% -78.47% -8.50% 51.27% -145.75% 1.35% -35.16% -16.15% -14.76% 43.54%
Net Income Q/Q Growth
72.48% 186.91% -329.86% 80.53% -302.91% -91.88% -2.52% -19.87% -66.75% -7.57%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-60.77% 32.37% 9.35% -115.18% 46.83% -249.14% -0.04% -18.21% 5.07% 10.42%
Free Cash Flow Firm Q/Q Growth
77.90% 264.62% -27.67% -115.98% -5,586.88% -58.32% -3.16% 0.06% 62.11% 110.00%
Invested Capital Q/Q Growth
69.35% -1,864.08% 26.54% 43.80% 552.99% 32.15% 5.98% 6.26% -20.11% -28.71%
Profitability Metrics
- - - - - - - - - -
Gross Margin
95.09% 98.91% 96.06% 92.01% 95.03% 90.50% 94.89% 19.69% 37.67% 88.66%
EBITDA Margin
-220.77% 302.52% -443.99% -46.34% -397.24% -143.63% -447.42% -369.81% -821.24% -136.62%
Operating Margin
-230.55% -460.58% -404.00% -73.81% -530.71% -117.31% -598.13% -534.84% -739.00% -128.01%
EBIT Margin
-234.62% 287.69% -446.47% -47.26% -399.38% -149.72% -493.02% -404.92% -865.01% -150.30%
Profit (Net Income) Margin
-230.20% 284.37% -416.15% -30.38% -358.10% -153.96% -485.31% -447.85% -899.19% -296.76%
Tax Burden Percent
99.50% 88.89% 99.23% 97.20% 101.74% 100.00% 99.58% 100.35% 100.00% 175.47%
Interest Burden Percent
98.61% 111.21% 93.94% 66.13% 88.13% 102.83% 98.85% 110.21% 103.95% 112.52%
Effective Tax Rate
0.00% 11.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -453.13% -205.33% -824.79% -501.28% -414.59% -69.88%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -453.71% -189.19% -819.84% -491.31% -377.52% 51.90%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 377.30% 158.85% 627.99% 319.14% 209.42% -20.94%
Return on Equity (ROE)
-31.24% -26.48% -39.53% -19.86% -75.83% -46.48% -196.80% -182.13% -205.18% -90.82%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -212.44% -234.58% -230.56% -240.86% -215.99% -157.45%
Operating Return on Assets (OROA)
-19.59% 23.55% -36.03% -6.80% -51.17% -28.59% -105.95% -76.76% -128.18% -20.25%
Return on Assets (ROA)
-19.23% 23.28% -33.58% -4.37% -45.88% -29.39% -104.30% -84.90% -133.24% -39.99%
Return on Common Equity (ROCE)
-31.24% -26.48% -39.53% -19.86% -75.83% -46.48% -196.80% -182.13% -205.18% -90.82%
Return on Equity Simple (ROE_SIMPLE)
-37.56% 0.00% -53.39% -24.32% -30.25% 0.00% -101.30% -205.70% -128.51% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.64 -8.28 -8.98 -4.38 -11 -11 -14 -17 -19 -11
NOPAT Margin
-161.38% -409.39% -282.80% -51.67% -371.50% -82.12% -418.69% -374.39% -517.30% -89.61%
Net Nonoperating Expense Percent (NNEP)
-1.75% 12.88% -4.20% 2.05% 0.58% -16.14% -4.96% -9.97% -37.07% -121.78%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -10.14% - - - -10.88%
Cost of Revenue to Revenue
4.91% 1.09% 3.94% 7.99% 4.97% 9.50% 5.11% 80.31% 62.33% 11.34%
SG&A Expenses to Revenue
138.27% 236.00% 227.55% 78.06% 200.97% 113.44% 289.96% 283.30% 438.65% 133.90%
R&D to Revenue
187.37% 323.49% 272.51% 87.76% 424.77% 88.40% 358.45% 236.48% 296.21% 69.35%
Operating Expenses to Revenue
325.64% 559.50% 500.06% 165.82% 625.73% 207.82% 693.02% 554.53% 776.67% 216.67%
Earnings before Interest and Taxes (EBIT)
-6.74 5.82 -14 -4.00 -12 -19 -17 -18 -32 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-6.35 6.12 -14 -3.93 -12 -19 -15 -16 -30 -16
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.29 2.11 2.66 2.52 2.42 3.83 4.30 6.31 5.23 11.22
Price to Tangible Book Value (P/TBV)
2.29 2.11 2.66 2.52 2.42 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
20.08 15.59 20.27 10.45 9.87 8.64 7.58 8.66 14.91 18.85
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 4.44 5.75 5.12 5.15 9.90 18.14
Enterprise Value to Revenue (EV/Rev)
11.26 6.72 11.48 5.93 7.49 7.73 7.23 9.04 13.42 18.18
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.14 0.17 0.18 0.19 0.65 0.69 0.88 1.80 0.84 1.50
Long-Term Debt to Equity
0.14 0.17 0.18 0.19 0.65 0.08 0.88 1.80 0.84 1.50
Financial Leverage
-1.00 -1.08 -1.04 -1.05 -0.83 -0.84 -0.77 -0.65 -0.55 -0.40
Leverage Ratio
1.14 1.23 1.20 1.37 1.60 2.10 2.15 2.48 2.41 3.45
Compound Leverage Factor
1.12 1.37 1.13 0.91 1.41 2.16 2.12 2.73 2.50 3.88
Debt to Total Capital
12.01% 14.56% 15.32% 15.65% 39.40% 40.87% 46.83% 64.23% 45.78% 60.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 36.03% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
12.01% 14.56% 15.32% 15.65% 39.40% 4.84% 46.83% 64.23% 45.78% 60.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
87.99% 85.44% 84.68% 84.35% 60.60% 59.13% 53.17% 35.77% 54.22% 40.00%
Debt to EBITDA
-0.36 -0.47 -0.33 -0.70 -1.87 -0.89 -0.87 -0.94 -0.73 -0.75
Net Debt to EBITDA
2.64 3.33 2.10 4.09 1.69 0.52 0.20 -0.15 0.45 0.20
Long-Term Debt to EBITDA
-0.36 -0.47 -0.33 -0.70 -1.87 -0.11 -0.87 -0.94 -0.73 -0.75
Debt to NOPAT
-0.51 -0.43 -0.34 -0.52 -1.43 -1.23 -1.07 -1.11 -0.97 -0.98
Net Debt to NOPAT
3.74 3.02 2.20 3.05 1.29 0.72 0.24 -0.17 0.60 0.26
Long-Term Debt to NOPAT
-0.51 -0.43 -0.34 -0.52 -1.43 -0.15 -1.07 -1.11 -0.97 -0.98
Altman Z-Score
2.18 -0.84 -0.32 -0.52 -1.21 -2.08 -2.55 -3.13 -1.65 -1.90
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
10.10 7.72 6.68 5.67 6.31 1.18 2.10 2.00 2.88 2.53
Quick Ratio
9.78 7.58 6.60 5.56 6.23 1.15 2.04 1.91 2.82 2.35
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.64 6.00 4.34 -0.69 -39 -62 -64 -64 -24 2.44
Operating Cash Flow to CapEx
-23,564.29% -13,123.53% -13,948.28% -37,843.48% -2,690.70% -22,441.67% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 -113.92 0.00 -34.98 -19.31 1.08
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -29.49 0.00 -10.39 -14.36 -7.17
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -29.62 0.00 -10.39 -14.36 -7.17
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.08 0.08 0.08 0.14 0.13 0.19 0.21 0.19 0.15 0.13
Accounts Receivable Turnover
2.61 2.07 1.68 1.96 2.01 2.14 3.44 2.06 2.76 1.69
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
12.03 12.11 11.87 20.77 22.17 35.90 38.51 34.66 39.21 43.25
Accounts Payable Turnover
0.40 0.05 0.05 0.14 0.11 0.13 0.18 0.38 0.43 0.28
Days Sales Outstanding (DSO)
139.62 176.50 216.97 185.93 181.92 170.64 106.21 177.04 132.03 215.53
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
922.50 7,568.82 6,826.25 2,668.47 3,272.75 2,903.54 2,003.72 959.19 851.15 1,325.23
Cash Conversion Cycle (CCC)
-782.88 -7,392.32 -6,609.29 -2,482.54 -3,090.83 -2,732.90 -1,897.51 -782.15 -719.12 -1,109.70
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-0.76 -15 -11 -6.16 28 37 39 42 33 24
Invested Capital Turnover
-40.76 -1.30 -2.18 -3.83 1.22 2.50 1.97 1.34 0.80 0.78
Increase / (Decrease) in Invested Capital
-0.99 -14 -13 -3.68 29 52 50 48 5.28 -13
Enterprise Value (EV)
121 68 108 98 124 212 200 214 329 429
Market Capitalization
215 158 190 173 164 237 210 205 365 445
Book Value per Share
$2.72 $2.18 $2.07 $2.02 $1.99 $1.71 $1.35 $0.78 $1.33 $0.74
Tangible Book Value per Share
$2.72 $2.18 $2.07 $2.02 $1.99 ($0.33) ($0.65) ($0.92) ($0.11) ($0.64)
Total Capital
107 88 84 81 111 105 92 91 129 99
Total Debt
13 13 13 13 44 43 43 58 59 60
Total Long-Term Debt
13 13 13 13 44 5.07 43 58 59 60
Net Debt
-95 -90 -82 -75 -40 -25 -9.72 9.07 -37 -16
Capital Expenditures (CapEx)
0.03 0.03 0.03 0.02 0.17 0.07 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.81 -2.04 -6.62 -2.20 32 -17 -20 -19 -24 -18
Debt-free Net Working Capital (DFNWC)
77 81 89 85 115 51 33 30 65 52
Net Working Capital (NWC)
77 81 89 85 115 13 33 30 65 52
Net Nonoperating Expense (NNE)
1.98 -14 4.24 -1.80 -0.39 9.28 2.28 3.27 14 25
Net Nonoperating Obligations (NNO)
-95 -90 -82 -75 -40 -25 -9.72 9.07 -37 -16
Total Depreciation and Amortization (D&A)
0.40 0.30 0.08 0.08 0.06 0.79 1.56 1.56 1.62 1.65
Debt-free, Cash-free Net Working Capital to Revenue
7.56% -20.04% -70.64% -13.28% 192.43% -61.25% -71.22% -79.43% -99.70% -74.26%
Debt-free Net Working Capital to Revenue
715.44% 795.31% 946.05% 514.90% 696.12% 185.42% 119.02% 128.51% 265.27% 220.07%
Net Working Capital to Revenue
715.44% 795.31% 946.05% 514.90% 696.12% 48.13% 119.02% 128.51% 265.27% 220.07%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.19) $0.16 ($0.34) ($0.15) ($0.40) ($0.54) ($0.40) ($0.48) ($0.69) ($0.71)
Adjusted Weighted Average Basic Shares Outstanding
34.49M 34.49M 34.47M 33.90M 34.72M 35.45M 41.78M 41.90M 47.81M 46.25M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
34.50M 34.54M 33.88M 33.93M 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
34.50M 34.54M 33.88M 33.93M 36.22M 43.43M 41.85M 52.62M 53.38M 54.12M
Normalized Net Operating Profit after Tax (NOPAT)
-4.64 -8.28 -8.98 -4.38 -11 -11 -14 -17 -19 -11
Normalized NOPAT Margin
-161.38% -409.39% -282.80% -51.67% -371.50% -82.12% -418.69% -374.39% -517.30% -89.61%
Pre Tax Income Margin
-231.35% 319.93% -419.40% -31.25% -351.99% -153.96% -487.36% -446.28% -899.19% -169.13%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -35.30 0.00 -9.79 -25.31 -7.98
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -19.36 0.00 -9.05 -15.13 -4.76
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -35.43 0.00 -9.79 -25.31 -7.98
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -19.49 0.00 -9.05 -15.13 -4.76
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-13.71% -17.64% -9.04% -20.29% -16.56% -7.49% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Zevra Therapeutics' Financials

When does Zevra Therapeutics's financial year end?

According to the most recent income statement we have on file, Zevra Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Zevra Therapeutics' net income changed over the last 2 years?

Zevra Therapeutics' net income appears to be on an upward trend, with a most recent value of -$105.51 million in 2024, rising from -$26.77 million in 2022. The previous period was -$46.05 million in 2023.

What is Zevra Therapeutics's operating income?
Zevra Therapeutics's total operating income in 2024 was -$87.00 million, based on the following breakdown:
  • Total Gross Profit: $16.20 million
  • Total Operating Expenses: $103.20 million
How has Zevra Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Zevra Therapeutics' total revenue changed from $10.16 million in 2022 to $23.61 million in 2024, a change of 132.4%.

How much debt does Zevra Therapeutics have?

Zevra Therapeutics' total liabilities were at $138.46 million at the end of 2024, a 25.3% increase from 2023, and a 244.3% increase since 2022.

How much cash does Zevra Therapeutics have?

In the past 2 years, Zevra Therapeutics' cash and equivalents has ranged from $33.79 million in 2024 to $65.47 million in 2022, and is currently $33.79 million as of their latest financial filing in 2024.

How has Zevra Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Zevra Therapeutics' book value per share changed from 2.18 in 2022 to 0.74 in 2024, a change of -65.9%.



This page (NASDAQ:ZVRA) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners